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c l i n i c a l  c o m m e n t a r y
Consider a protocol to identify patients 
needing prophylaxis inthe ICU
Many	patients	may	enter	the	hospital	
already	on	a	PPI	for	reflux	disease	or		
prevention	of	gastrointestinal	side		
effects	from	other	medications.	This		
Clinical	Inquiry	shows	that	only	certain	
patients	in	the	hospital	will	benefit	from	
prophylaxis	for	stress	ulcers	and	have	less	
bleeding.	Therefore,	consider	using	a		
protocol	to	identify	those	specific	pa-
tients	in	the	ICu	and	place	them	on	an	H2	
blocker,	PPI	or	sucralfate	automatically.		
Julia Fashner, MD
Wright	state	university	Boonshoft	school	of	Medi-
cine,	Detroit,	Mich
e v i d e n c e - b a s e d  a n s w e r
Patients	in	intensive	care	unit	(ICe)		
settings	who	are	receiving	prolonged		
mechanical	ventilation	(for	>48	hours)	
or	who	have	a	coagulopathy	or	multiple	
organ	dysfunction	(especially	renal	failure)	
should	receive	stress	ulcer	prophylaxis.	
Current	evidence	does	not	support		
prophylaxis	for	non-ICu	patients1,2	
(strength	of	recommendation	[sor]:	B,	
based	on	multiple	systematic	reviews).
			Prophylaxis	with	H2	receptor	antago-
nists	(H2ras)	and	sucralfate	are	equally	
efficacious	in	lowering	mortality	and	
length	of	hospital	stay.3	No	randomized	
controlled	trials	demonstrate	that	proton	
pump	inhibitors	(PPIs)	are	superior	to	
H2ras	or	sucralfate	(sor:	B,	based	on	
multiple	systematic	reviews.)		
What GI stress ulcer  
prophylaxis should we provide 
hospitalized patients?
æ Evidence Summary 
Critically ill patients are at increased risk 
of bleeding from stress-induced gastro-
duodenal ulceration. Decades ago, ICUs 
began using pharmacologic prophylaxis 
on most patients to prevent gastrointesti-
nal bleeding, which had a mortality rate 
as high as 80%. Before the advent of pro-
phylaxis, the incidence of upper gastro- 
intestinal bleeding was 6% to 25%.4 Since 
then, improvements in ICU management 
have decreased this incidence to 0% to 
2.8%.5 Recent studies suggest that only 
ICU patients with certain risk factors ben-
efit from ulcer prophylaxis (TablE).1
Our search retrieved 20 randomized 
controlled trials and 6 systematic reviews 
with meta-analyses from the Medline 
database since 1990. It was difficult to 
find a consensus on the matter of stress ul-
cer prophylaxis because of inconsistencies 
in the outcomes measured in these studies. 
We focused on studies examining clini-
cally important bleeding, but even in these 
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studies definitions and measurements 
vary. Few studies addressed mortality or 
length of stay; those that did reported no 
significant difference in either outcome 
with prophylaxis. 
Medications used to prevent gastro-
intestinal bleeding have included antacids, 
sucralfate, H2RAs, and PPIs. Sucralfate 
and H2RAs have been studied most fre-
quently, and both agents significantly re-
duce the incidence of clinically important 
bleeding in high-risk patients. Compared 
with placebo, the odds ratio for clinically 
important bleeding was 0.44 with raniti-
dine (95% confidence interval [CI], 0.22–
0.88) and 0.58 with sucralfate (95% CI, 
0.34–0.99).6 In a population with a clini-
cally important bleeding incidence of 3% 
to 6%, a range consistent with the most 
recent studies we reviewed, the number 
needed to treat to prevent 1 bleeding epi-
sode is 30 to 60 for ranitidine and 40 to 
79 for sucralfate. 
Some studies suggest that pharma-
cologic prophylaxis may increase the 
incidence of aspiration pneumonia in 
ventilator-dependent patients. The larg-
est randomized trial addressing this issue 
(N=1200) found no significant difference 
between H2RAs and sucralfate in ventila-
tor-associated pneumonia.3 Improved ICU 
management, such as frequent suctioning, 
upright positioning, and use of enteral 
nutrition may help prevent nosocomial 
pneumonia due to aspiration.
recommendation from others
In the American Journal of Health-System 
Pharmacy, Allen et al5 state “the frequency 
of clinically important bleeding is low … 
the majority of recently published pro-
spective studies and meta-analyses have 
been unable to demonstrate a reduction 
in clinically important bleeding with phar-
macologic agents.” A 2001 Agency for 
Healthcare Research and Quality evidence 
report7 states that the evidence is not con-
clusive that all intensive care patients ben-
efit from stress ulcer prophylaxis and that 
clinicians “may consider use of prophylac-
tic agents in very high risk patients.”
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Risk factors for stress ulcers
 odds raTIos for ClInICally  
sTress UlCer rIsk faCTors ImPorTanT BleedIng (95% CI)
Mechanical	ventilation	>48	hours5	 3.4	(1.0–11)	
Platelet	count	<50,0001,2	 2.58	(1.19–5.57)	
Maximum	serum	creatinine1	 1.16	(1.02–1.32)
t a b l e
Sucralfate and 
H2RAs reduce  
rates of clinically 
important  
bleeding for those 
in ICUs
